GB0615327D0 - Culture medium containing kinase inhibitors and uses thereof - Google Patents

Culture medium containing kinase inhibitors and uses thereof

Info

Publication number
GB0615327D0
GB0615327D0 GBGB0615327.4A GB0615327A GB0615327D0 GB 0615327 D0 GB0615327 D0 GB 0615327D0 GB 0615327 A GB0615327 A GB 0615327A GB 0615327 D0 GB0615327 D0 GB 0615327D0
Authority
GB
United Kingdom
Prior art keywords
culture medium
medium containing
kinase inhibitors
containing kinase
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0615327.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Edinburgh
Original Assignee
University of Edinburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0606392.9A external-priority patent/GB0606392D0/en
Priority to GBGB0615327.4A priority Critical patent/GB0615327D0/en
Application filed by University of Edinburgh filed Critical University of Edinburgh
Publication of GB0615327D0 publication Critical patent/GB0615327D0/en
Priority to GBGB0700479.9A priority patent/GB0700479D0/en
Priority to US11/694,351 priority patent/US9074180B2/en
Priority to EP07732217A priority patent/EP1999249B8/en
Priority to AT07732217T priority patent/ATE530637T1/en
Priority to EP11182239A priority patent/EP2457995A1/en
Priority to JP2009502219A priority patent/JP5680850B2/en
Priority to AU2007232393A priority patent/AU2007232393A1/en
Priority to PCT/GB2007/001163 priority patent/WO2007113505A2/en
Priority to TW096111227A priority patent/TW200815597A/en
Priority to GB0706239A priority patent/GB2436737B/en
Priority to CA002645170A priority patent/CA2645170A1/en
Priority to US11/832,317 priority patent/US8431395B2/en
Priority to JP2009522328A priority patent/JP5456467B2/en
Priority to PCT/GB2007/002913 priority patent/WO2008015418A2/en
Priority to CN200780036720.1A priority patent/CN101657535B/en
Priority to GB0716426A priority patent/GB2451523B/en
Priority to EP07766403A priority patent/EP2049654A2/en
Priority to AU2007280216A priority patent/AU2007280216B2/en
Priority to CN201410720584.XA priority patent/CN104531610A/en
Priority to IL193495A priority patent/IL193495A0/en
Priority to US12/581,981 priority patent/US20100041137A1/en
Priority to JP2013011454A priority patent/JP5728036B2/en
Priority to US13/857,449 priority patent/US20130333058A1/en
Priority to JP2013127052A priority patent/JP2013176400A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0273—Cloned animals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/101—Bovine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/103—Ovine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/108—Swine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes

Abstract

Pluripotent cells are derived and maintained in a self-renewing state in serum-free culture medium comprising a MEK inhibitor, a GSK3 inhibitor and an antagonist of an FGF receptor.
GBGB0615327.4A 2006-03-30 2006-08-01 Culture medium containing kinase inhibitors and uses thereof Ceased GB0615327D0 (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
GBGB0615327.4A GB0615327D0 (en) 2006-03-30 2006-08-01 Culture medium containing kinase inhibitors and uses thereof
GBGB0700479.9A GB0700479D0 (en) 2006-08-01 2007-01-10 Culture medium containing kinase inhibitors, and uses thereof
CA002645170A CA2645170A1 (en) 2006-03-30 2007-03-30 Culture medium containing kinase inhibitors, and uses thereof
GB0706239A GB2436737B (en) 2006-03-30 2007-03-30 Culture medium containing kinase inhibitors,and uses thereof
EP07732217A EP1999249B8 (en) 2006-03-30 2007-03-30 Culture medium containing kinase inhibitors. and uses thereof
US11/694,351 US9074180B2 (en) 2006-03-30 2007-03-30 Culture medium containing kinase inhibitors, and uses thereof
AT07732217T ATE530637T1 (en) 2006-03-30 2007-03-30 CULTURE MEDIA CONTAINING KINASE INHIBITORS AND USE
EP11182239A EP2457995A1 (en) 2006-03-30 2007-03-30 Culture medium containing kinase inhibitors, and uses thereof
JP2009502219A JP5680850B2 (en) 2006-03-30 2007-03-30 Culture medium containing kinase inhibitor and use thereof
AU2007232393A AU2007232393A1 (en) 2006-03-30 2007-03-30 Culture medium containing kinase inhibitors. and uses thereof
PCT/GB2007/001163 WO2007113505A2 (en) 2006-03-30 2007-03-30 Culture medium containing kinase inhibitors. and uses thereof
TW096111227A TW200815597A (en) 2006-03-30 2007-03-30 Culture medium containing kinase inhibitors, and uses thereof
CN201410720584.XA CN104531610A (en) 2006-08-01 2007-08-01 Pluripotent cells from rat and other specie
US11/832,317 US8431395B2 (en) 2006-08-01 2007-08-01 Pluripotent cells from rat and other species
JP2009522328A JP5456467B2 (en) 2006-08-01 2007-08-01 Pluripotent cells from rats and other species
AU2007280216A AU2007280216B2 (en) 2006-08-01 2007-08-01 Pluripotent cells from rat and other species
PCT/GB2007/002913 WO2008015418A2 (en) 2006-08-01 2007-08-01 Pluripotent cells from rat and other species
CN200780036720.1A CN101657535B (en) 2006-08-01 2007-08-01 Come from the multipotential cell of rat and other animal
GB0716426A GB2451523B (en) 2006-08-01 2007-08-01 Pluripotent cells from rat and other species
EP07766403A EP2049654A2 (en) 2006-08-01 2007-08-01 Pluripotent cells from rat and other species
IL193495A IL193495A0 (en) 2006-03-30 2008-08-17 Culture medium containing kinase inhibitors and uses thereof
US12/581,981 US20100041137A1 (en) 2006-03-30 2009-10-20 Culture medium containing kinase inhibitors, and uses thereof
JP2013011454A JP5728036B2 (en) 2006-03-30 2013-01-24 Culture medium containing kinase inhibitor and use thereof
US13/857,449 US20130333058A1 (en) 2006-08-01 2013-04-05 Pluripotent Cells From Rat and Other Species
JP2013127052A JP2013176400A (en) 2006-08-01 2013-06-17 Pluripotent cell derived from rat and other species

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0606392.9A GB0606392D0 (en) 2006-03-30 2006-03-30 Culture medium containing kinase inhibitors, and uses thereof
GBGB0615327.4A GB0615327D0 (en) 2006-03-30 2006-08-01 Culture medium containing kinase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
GB0615327D0 true GB0615327D0 (en) 2006-09-13

Family

ID=37809760

Family Applications (3)

Application Number Title Priority Date Filing Date
GBGB0615327.4A Ceased GB0615327D0 (en) 2006-03-30 2006-08-01 Culture medium containing kinase inhibitors and uses thereof
GBGB0700479.9A Ceased GB0700479D0 (en) 2006-08-01 2007-01-10 Culture medium containing kinase inhibitors, and uses thereof
GB0716426A Expired - Fee Related GB2451523B (en) 2006-08-01 2007-08-01 Pluripotent cells from rat and other species

Family Applications After (2)

Application Number Title Priority Date Filing Date
GBGB0700479.9A Ceased GB0700479D0 (en) 2006-08-01 2007-01-10 Culture medium containing kinase inhibitors, and uses thereof
GB0716426A Expired - Fee Related GB2451523B (en) 2006-08-01 2007-08-01 Pluripotent cells from rat and other species

Country Status (7)

Country Link
US (2) US8431395B2 (en)
EP (1) EP2049654A2 (en)
JP (2) JP5456467B2 (en)
CN (2) CN101657535B (en)
AU (1) AU2007280216B2 (en)
GB (3) GB0615327D0 (en)
WO (1) WO2008015418A2 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
US8357666B2 (en) * 2005-08-01 2013-01-22 Nupotential, Inc. Reprogramming a cell by inducing a pluripotent gene through RNA interference
TW200815597A (en) * 2006-03-30 2008-04-01 Univ Edinburgh Culture medium containing kinase inhibitors, and uses thereof
CA2683056C (en) 2007-04-07 2020-03-24 Whitehead Institute For Biomedical Research Reprogramming of somatic cells
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
JP5722628B2 (en) * 2007-07-18 2015-05-27 セレクティス アーベー hBS cell-derived cardiomyocyte-like cell cluster
EP2185693B1 (en) 2007-07-31 2019-07-03 Lifescan, Inc. Differentiation of human embryonic stem cells
CN101855338B (en) * 2007-08-31 2013-07-17 怀特黑德生物医学研究所 WNT pathway stimulation in reprogramming somatic cells
ES2690554T3 (en) 2008-03-17 2018-11-21 The Scripps Research Institute Combined chemical and genetic approaches for the generation of induced pluripotent stem cells
EP2276834A4 (en) * 2008-04-07 2012-02-08 Nupotential Inc Reprogramming a cell by inducing a pluripotent gene through use of a small molecule modulator
EP2300611B1 (en) 2008-06-13 2017-08-09 Whitehead Institute for Biomedical Research Programming and reprogramming of cells
ES2697798T3 (en) 2008-06-30 2019-01-28 Janssen Biotech Inc Differentiation of pluripotent stem cells
US8735156B2 (en) 2008-12-01 2014-05-27 The Board Of Regents Of The University Of Texas System Production and use of rat spermatogonial stem cell lines
EP2373784B1 (en) * 2008-12-17 2017-10-25 The Scripps Research Institute Generation and maintenance of stem cells
WO2010124290A2 (en) * 2009-04-24 2010-10-28 Whitehead Institute For Biomedical Research Compositions and methods for deriving or culturing pluripotent cells
BR112012008848A2 (en) * 2009-10-16 2019-09-24 Scripps Research Inst in vitro or ex vivo method for inducing non-pluripotent mammalian cells into induced pluripotent stem cells
EP2508595B1 (en) 2009-12-01 2016-11-23 National Cancer Center Method for constructing chimeric rat using rat embryonic stem cells
US8932853B2 (en) 2009-12-29 2015-01-13 Takeda Pharmaceutical Company Limited Method for manufacturing pancreatic-hormone-producing cells
JP5909482B2 (en) 2010-03-31 2016-04-26 ザ スクリプス リサーチ インスティテュート Cell reprogramming
US20130059375A1 (en) * 2010-04-02 2013-03-07 Riken Method for preparing es cells
US9376664B2 (en) 2010-06-14 2016-06-28 The Scripps Research Institute Reprogramming of cells to a new fate
CN102344490B (en) * 2010-07-30 2014-03-05 中国科学院上海生命科学研究院 Anti-mouse Stk40 polyclonal antibody and preparation thereof
KR101877077B1 (en) * 2010-08-09 2018-07-10 다케다 야쿠힌 고교 가부시키가이샤 Method of producing pancreatic hormone-producing cells
EP2640829A4 (en) * 2010-11-17 2014-06-11 Univ Kyoto Cardiomyocyte- and/or cardiac progenitor cell-proliferating agent and method for proliferating cardiomyocytes and/or cardiac progenitor cells
WO2012087965A2 (en) 2010-12-22 2012-06-28 Fate Therapauetics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
WO2012101619A1 (en) * 2011-01-24 2012-08-02 Ben Gurion University Of The Negev Research And Development Authority A method for evaluating a mental disorder
CN108220224A (en) 2011-06-21 2018-06-29 诺沃—诺迪斯克有限公司 Definitive entoderm is effectively induced from pluripotent stem cell
RU2664232C2 (en) 2011-08-05 2018-08-15 Регенерон Фармасьютикалз, Инк. Humanised universal light chain mice
DK2793567T3 (en) 2011-12-20 2019-04-15 Regeneron Pharma Humanized light chain mice
SG10201702445TA (en) 2012-04-25 2017-04-27 Regeneron Pharma Nuclease-mediated targeting with large targeting vectors
ES2904803T3 (en) * 2013-02-20 2022-04-06 Regeneron Pharma Genetic modification of rats
RS58255B1 (en) 2013-04-16 2019-03-29 Regeneron Pharma Targeted modification of rat genome
CA2915097C (en) 2013-06-14 2021-12-07 The University Of Queensland Renal progenitor cells
WO2015088643A1 (en) 2013-12-11 2015-06-18 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
EP3114214B1 (en) 2014-03-04 2023-11-01 Fate Therapeutics, Inc. Improved reprogramming methods and cell culture platforms
US20170165230A1 (en) 2014-04-09 2017-06-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
JP6652334B2 (en) 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 Medium containing uridine and N-acetyl-D-mannosamine
RU2704283C9 (en) 2014-06-06 2020-02-07 Регенерон Фармасьютикалз, Инк. Methods and compositions for modifying target locus
ES2694629T3 (en) 2014-06-26 2018-12-26 Regeneron Pharmaceuticals, Inc. Methods and compositions for objective genetic modifications and methods of use
PT3221457T (en) 2014-11-21 2019-06-27 Regeneron Pharma Methods and compositions for targeted genetic modification using paired guide rnas
KR102530821B1 (en) 2014-12-19 2023-05-10 리제너론 파마슈티칼스 인코포레이티드 Methods and compositions for targeted genetic modification through single-step multiple targeting
KR20170132281A (en) * 2015-03-30 2017-12-01 아지노모토 가부시키가이샤 Neural stem cell proliferation medium containing human serum albumin
CN117737124A (en) 2015-10-16 2024-03-22 菲特治疗公司 Platform for inducing and maintaining ground state pluripotency
MA45479A (en) 2016-04-14 2019-02-20 Janssen Biotech Inc DIFFERENTIATION OF PLURIPOTENT STEM CELLS IN ENDODERMAL CELLS OF MIDDLE INTESTINE
US11268950B2 (en) 2016-09-28 2022-03-08 Organovo, Inc. Use of engineered renal tissues in assays
US20210246429A1 (en) * 2018-04-27 2021-08-12 Kaneka Corporation Method for producing primitive gut tube cells
US20230034359A1 (en) * 2018-11-21 2023-02-02 Agency For Science, Technology And Research Generation of mature kupffer cells
CN111238897B (en) * 2020-02-18 2023-03-28 上海市皮肤病医院 Method and agent for treating biological specimen
WO2023017806A1 (en) * 2021-08-10 2023-02-16 株式会社カネカ Method for producing pluripotent stem cells

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9308271D0 (en) 1993-04-21 1993-06-02 Univ Edinburgh Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method
WO1995006716A1 (en) 1993-08-30 1995-03-09 Northwestern University Rat pluripotent embryonic stem cells and method of obtaining and using same
EP0941310A1 (en) * 1996-10-11 1999-09-15 THE TEXAS A&M UNIVERSITY SYSTEM Methods for the generation of primordial germ cells and transgenic animal species
US6214795B1 (en) * 1996-11-12 2001-04-10 Praecis Pharmaceuticals, Inc. Peptide compounds useful for modulating FGF receptor activity
WO1998030679A1 (en) 1997-01-10 1998-07-16 Life Technologies, Inc. Embryonic stem cell serum replacement
WO1999027076A1 (en) * 1997-11-25 1999-06-03 Arc Genomic Research Pluripotent embryonic stem cells and methods of obtaining them
GB9819912D0 (en) 1998-09-11 1998-11-04 Univ Edinburgh Propagation and/or derivation of embryonic stem cells
US7455983B2 (en) * 2000-01-11 2008-11-25 Geron Corporation Medium for growing human embryonic stem cells
US20020045260A1 (en) * 2000-10-17 2002-04-18 Shih-Chieh Hung Method of isolating mesenchymal stem cells
JP2002176973A (en) 2000-12-14 2002-06-25 Shigeo Saito Mammalian embryonic stem cell and method for establishing the same and subculture method for the same
EP1480515B1 (en) 2002-03-05 2005-10-19 ARTEMIS Pharmaceuticals GmbH Inbred embryonic stem-cell derived mice
GB0210539D0 (en) 2002-05-08 2002-06-19 Univ Edinburgh Control of es cell self renewal and lineage specification, and medium therefor
US7338957B2 (en) 2003-08-28 2008-03-04 Irm Llc Compounds and compositions as protein kinase inhibitors
US7704738B2 (en) * 2003-12-23 2010-04-27 Cythera, Inc. Definitive endoderm
US8137966B2 (en) * 2004-03-04 2012-03-20 Dainippon Sumitomo Pharma Co., Ltd. Rat embryonic stem cell
EP1740184A1 (en) 2004-03-30 2007-01-10 Pfizer Products Incorporated Combinations of signal transduction inhibitors
WO2005110438A2 (en) * 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the intracellular delivery of polysaccharides
US20080268533A1 (en) 2004-08-25 2008-10-30 University Of Georgia Research Foundation, Inc. Methods and Compositions Utilizing Myc and Gsk3Beta to Manipulate the Pluripotency of Embryonic Stem Cells
MX2007015610A (en) 2005-06-10 2008-02-21 Irm Llc Compounds that maintain pluripotency of embryonic stem cells.
AU2006318327B2 (en) 2005-11-28 2011-08-18 Choongwae Pharma Corporation Serum-free expansion of cells in culture
TW200815597A (en) * 2006-03-30 2008-04-01 Univ Edinburgh Culture medium containing kinase inhibitors, and uses thereof
WO2007113705A1 (en) * 2006-04-03 2007-10-11 Koninklijke Philips Electronics N. V. Determining tissue surrounding an object being inserted into a patient
BRPI0711628A2 (en) 2006-05-15 2011-12-06 Irm Llc compound, pharmaceutical composition, use and process for preparing the compound

Also Published As

Publication number Publication date
JP2013176400A (en) 2013-09-09
GB2451523A (en) 2009-02-04
CN104531610A (en) 2015-04-22
GB2451523B (en) 2010-03-17
AU2007280216B2 (en) 2012-12-20
GB2451523A8 (en) 2009-02-18
GB0716426D0 (en) 2007-10-10
CN101657535B (en) 2016-03-02
WO2008015418A3 (en) 2008-04-10
US20080066197A1 (en) 2008-03-13
GB0700479D0 (en) 2007-02-21
CN101657535A (en) 2010-02-24
WO2008015418A2 (en) 2008-02-07
EP2049654A2 (en) 2009-04-22
JP5456467B2 (en) 2014-03-26
JP2009545302A (en) 2009-12-24
US20130333058A1 (en) 2013-12-12
AU2007280216A1 (en) 2008-02-07
US8431395B2 (en) 2013-04-30

Similar Documents

Publication Publication Date Title
GB0615327D0 (en) Culture medium containing kinase inhibitors and uses thereof
WO2007113505A3 (en) Culture medium containing kinase inhibitors. and uses thereof
WO2010008486A3 (en) Pluripotent cell lines and methods of use thereof
EP1988159A4 (en) Additive for culture medium for use in serum-free culture of animal cell, kit, and use of the additive or kit
MY153727A (en) Pyridazinone derivatives
GB0621792D0 (en) Composition
GB0602063D0 (en) Cell Culture
EP3153023B8 (en) Benzoxazole kinase inhibitors and methods of use
MX2009012708A (en) Pyridazinone derivatives.
UA99311C2 (en) Inhibitors of c-fms kinase
MX339584B (en) Pi3 kinase inhibitors and uses thereof.
EP2114983B8 (en) Axl tyrosine kinase inhibitors and methods of making and using the same
EP2021534A4 (en) Assessment and reduction of risk of graft-versus-host disease
MX343669B (en) Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors.
WO2007025247A3 (en) Transglutaminase inhibitors and methods of use thereof
SG196784A1 (en) Stem cell cultures
TN2011000207A1 (en) Akt and p70 s6 kinase inhibitors
WO2007050795A3 (en) Transglutaminase inhibitors and methods of use thereof
MX2009013982A (en) Compositions comprising tryptophan hydroxylase inhibitors.
EP2024814A4 (en) Systems and methods for consumer-generated media reputation management
TN2009000151A1 (en) Mapk/erk kinase inhibitors
MX2008009830A (en) Bst2 inhibitor.
MX2009008122A (en) Pharmaceutical compositions and methods of using temozolomide and multi-targeted kinase inhibitors.
SG151171A1 (en) Association between an anti-atherothrombotic and an angiotensin- converting enzyme inhibitor
WO2007109067A3 (en) Non-random aptamer libraries and methods for making

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)